MedTrace Logo

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

NCT00144807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2015-09-02

No results posted yet for this study

Summary

This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma

Conditions

  • Diffuse Large Cell Lymphoma

Interventions

DRUG

rituximab

DRUG

doxorubicin

DRUG

cyclophosphamide

PROCEDURE

autologous stem cell transplantation

Sponsors & Collaborators

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Olivier Fitoussi, MD · Lymphoma Study Association

  • Christian Gisselbrecht, MD · Lymphoma Study Association

  • Corinne Haioun, MD · Lymphoma Study Association

  • Hervé Tilly, MD · Lymphoma Study Association

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-09-30
Completion
2012-04-30

Countries

  • Belgium
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144807 on ClinicalTrials.gov